Venetoclax
- Generic Name
- Venetoclax
- Brand Names
- Venclexta, Venclyxto
- Drug Type
- Small Molecule
- Chemical Formula
- C45H50ClN7O7S
- CAS Number
- 1257044-40-8
- Unique Ingredient Identifier
- N54AIC43PW
- Background
Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 . Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphoma . CLL is the most prevalent leukemia diagnosed in Western countries . Venetoclax was developed through reverse engineering of the BCL-2 protein family inhibitor, navitoclax . Venetoclax is approximately 10 times more potent than navitoclax with regard to induction of apoptosis in CLL cells . A new indication was approved in 2018 for the treatment patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy . Previously, this drug was indicated only for patients with 17p gene deletion .
- Indication
本品与阿扎胞苷联合用于治疗因合并症不适合接受强诱导化疗，或者年龄75岁及以上的新诊断的成人急性髓系白血病患者。
- Associated Conditions
- Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Associated Therapies
- -
Activity and Safety of Front-line Venetoclax and Rituximab in Young and Fit Patients With Chronic Lymphocytic Leukemia
- First Posted Date
- 2018-03-06
- Last Posted Date
- 2023-11-24
- Target Recruit Count
- 77
- Registration Number
- NCT03455517
- Locations
- 🇮🇹
Ao Di Perugia, Ospedale S. Maria Della Misericordia - Ematologia E Trapianto Midollo Osseo, Perugia, Italy
🇮🇹Fondazione Policlinico Universitario Agostino Gemelli Irccs - Roma - Area Ematologica, Roma, Italy
🇮🇹Università degli Studi di Roma "Sapienza", Roma, Italy
Venetoclax Add in Combination With Fludarabine, Cyratabine and Idarubicine in Induction for Acute Myelid Leukemia
- First Posted Date
- 2018-03-06
- Last Posted Date
- 2024-04-10
- Target Recruit Count
- 124
- Registration Number
- NCT03455504
- Locations
- 🇮🇹
Aou Senese - Uoc Ematologia E Trapianti, Siena, Italy
🇮🇹Spedali Civili - Azienda Ospedaliera U.O. Ematologia, Brescia, Italy
🇮🇹Asl Salerno, Presidio Ospedaliero Tortora Pagani - Ematologia, Pagani, Italy
A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- First Posted Date
- 2018-02-22
- Last Posted Date
- 2022-02-01
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 36
- Registration Number
- NCT03441555
- Locations
- 🇩🇪
Univ Klinik Eppendorf Hamburg /ID# 168633, Hamburg, Germany
🇺🇸NYU Langone Medical Center /ID# 201559, New York, New York, United States
🇺🇸University of Pittsburgh Medic /ID# 170790, Pittsburgh, Pennsylvania, United States
Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib
- Conditions
- Interventions
- First Posted Date
- 2018-02-05
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Michael Choi
- Target Recruit Count
- 24
- Registration Number
- NCT03422393
- Locations
- 🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States
A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy
- Conditions
- Interventions
- First Posted Date
- 2018-01-23
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 120
- Registration Number
- NCT03406156
- Locations
- 🇺🇸
Oncology Hematology Care, Inc. /ID# 202397, Cincinnati, Ohio, United States
🇺🇸Tennessee Oncology-Nashville Centennial /ID# 201098, Nashville, Tennessee, United States
🇺🇸Arizona Oncology Associates, PC-HOPE /ID# 202335, Tempe, Arizona, United States
Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome
- Conditions
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeRecurrent Chronic Myelomonocytic LeukemiaRefractory Blastic Plasmacytoid Dendritic Cell NeoplasmAcute Myeloid LeukemiaBlastic Plasmacytoid Dendritic Cell NeoplasmChronic Myelomonocytic LeukemiaMixed Phenotype Acute LeukemiaRecurrent Blastic Plasmacytoid Dendritic Cell NeoplasmRecurrent Mixed Phenotype Acute LeukemiaRefractory Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2018-01-19
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 235
- Registration Number
- NCT03404193
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients with Relapsed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2018-01-16
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 8
- Registration Number
- NCT03399539
- Locations
- 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Siteman Cancer Center at Washington University, Saint Louis, Missouri, United States
OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia
- First Posted Date
- 2018-01-04
- Last Posted Date
- 2023-09-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT03390296
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL
- Conditions
- Interventions
- First Posted Date
- 2017-12-20
- Last Posted Date
- 2022-08-22
- Lead Sponsor
- TG Therapeutics, Inc.
- Target Recruit Count
- 78
- Registration Number
- NCT03379051
- Locations
- 🇺🇸
TG Therapeutics Investigational Trial Site, Cleveland, Ohio, United States
A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2017-11-30
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Calithera Biosciences, Inc
- Target Recruit Count
- 43
- Registration Number
- NCT03357627
- Locations
- 🇨🇦
Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada
🇺🇸Ingalls Memorial Hospital, Harvey, Illinois, United States
🇨🇦Jewish General Hospital, Montreal, Quebec, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.